Please login to the form below
Ozurdex
This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.
NICE backs Bayer's Eylea in diabetic eye condition
NICE backs Bayer's Eylea in diabetic eye condition. TheInstitute also recommends Allergan's Ozurdex in final guidance. ... Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO).
Latest news
-
NICE recommends Ozurdex for diabetic eye condition
NICE recommends Ozurdex for diabetic eye condition. Draft guidance cites implant as option for patients with diabetic macular oedema. ... Ozurdex is injected into the eye once every six months and works by suppressing inflammation and preventing oedema
-
Fresh approval for Roche's Lucentis as competition heats up
Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
-
New eye indication for Allergan’s Ozurdex
New eye indication for Allergan’ s Ozurdex. EU approval extends the drug's use to diabetic macular oedema. ... Ozurdex joins a competitive market for DMO, with approved drugs in the EU including Novartis' Lucentis (ranibizumab).
-
Allergan will start phase III DARPin trials next year
On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have
-
NICE against new indication for Novartis' Lucentis
Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Allergan and taking a specialised approach
spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Scientific Director
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
Subscribe to our email news alerts
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
